-
Mashup Score: 20
Nature Cancer – Ye and colleagues show that an oncolytic virus that delivers tumor-irrelevant bystander T cell epitopes to tumor cells can exploit the abundant population of bystander T cells in…
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 37
A new drug could offer a powerful way to sensitise tumours to immunotherapy, a new trial suggests.
Source: www.icr.ac.ukCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 34
Background Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite their potential, these therapies have had limited success in late-phase trials for advanced cancer resulting in few formal approvals. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to determine how to design clinical trials with the greatest chance of demonstrating the benefits of intratumoral immunotherapy for patients with cancers across all stages of pathogenesis. Methods An Intratumoral Immunotherapy Clinical Trials Expert Panel composed of international key stakeholders from academia and industry was assembled. A multiple choice/free response survey was distributed to the panel, and the results of this survey were discussed during a half-day consensus meeting. Key discussion points are summarized in the follow
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 20Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy - 12 day(s) ago
Abstract. Tumor-associated tertiary lymphoid structures (TLS) have been associated with favorable clinical outcomes and response to immune checkpoint inhibitors in many cancer types, including non–small cell lung cancer. Although the detailed cellular and molecular mechanisms underlying these clinical associations have not been fully elucidated, growing preclinical and clinical studies are helping to elucidate the mechanisms at the basis of TLS formation, composition, and regulation of immune responses. However, a major challenge remains how to exploit TLS to enhance naïve and treatment-mediated antitumor immune responses. Here, we discuss the current understanding of tumor-associated TLS, preclinical models that can be used to study them, and potential therapeutic interventions to boost TLS formation, with a particular focus on lung cancer research.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Immunotherapy Testing Recommendations Released - 15 day(s) ago
In collaboration with several organizations, the College of American Pathologists (CAP) has released recommendations for testing of immunotherapy biomarkers, including PD-L1 and tumor mutation burden, in patients with non–small cell lung cancer (NSCLC). The guidelines, developed with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and LUNGevity Foundation, outline the challenges associated with PD-L1 testing and assessment, including the development of nonuniform companion diagnostic tests (Arch Pathol Lab Med 2024 Apr 16 [Epub ahead of print]). It also explains the rationale for the use of tumor mutation burden and the limitations of these tests for patients with NSCLC. CAP noted that the development of the guidelines was “driven by production of PD-L1 assays and scoring criteria that have evolved with individual therapies. At the same time, for reasons of cost and access, PD-L1 IHC antibodies and assays dev
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 54FDA Approves Toripalimab for Advanced Nasopharyngeal Cancer - 22 day(s) ago
Adding toripalimab (Loqtorzi) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
Source: www.cancer.govCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9What to know about TIL therapy, a new treatment for skin cancer - 23 day(s) ago
Content team needs to fill this in. The Social Sharing description and the twitter text will be the same.
Source: health.osu.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Novel Mechanism Supports Antitumor Response and T-cell Survival - 25 day(s) ago
A recent Northwestern Medicine study has discovered a previously unknown molecular mechanism that supports antitumor responses and cell survival in cytotoxic immune cells, according to findings published in the Journal of Clinical Investigation.
Source: news.feinberg.northwestern.eduCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials - 1 month(s) ago
AbstractBackground. Relapse-free survival (RFS) has been considered a primary endpoint to assess the effects of immunotherapy in the adjuvant setting among
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy - 1 month(s) ago
Abstract. Activation of effector T cells leads to upregulation of PD-1, which can inhibit T-cell activity following engagement with its ligand PD-L1. Post-translational modifications (PTM), including glycosylation, phosphorylation, ubiquitination, and palmitoylation, play a significant role in regulating PD-1 protein stability, localization, and interprotein interactions. Targeting PTM of PD-1 in T cells has emerged as a potential strategy to overcome PD-1–mediated immunosuppression in cancer and enhances antitumor immunity. The regulatory signaling pathways that induce PTM of PD-1 can be suppressed with small-molecule inhibitors, and mAbs can directly target PD-1 PTMs. Preliminary outcomes from exploratory studies suggest that focusing on the PTM of PD-1 has strong therapeutic potential and can enhance the response to anti-PD-1.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
✨ONLINE NOW @NatureCancer “An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy” #immunotherapy https://t.co/LAMAmIDM25